"The research and development of biomedicine has entered the era of drug screening and design for specific biological effect targets." As the initiator of Zhongguancun AI new drug R&D platform, Zhou Yiming, founder of Kakuei Bio, said that in recent years, with the breakthrough of various Qualcomm detection technologies, the amount of data such as genome, transcriptome and proteome has increased exponentially, which has far exceeded the analytical ability of traditional statistical methods.
Yiming Zhou believes that artificial intelligence technology has developed by leaps and bounds in recent years, and it has the ability to process massive medical data based on more powerful algorithms and computing power. Therefore, the research and development of innovative drugs has entered the era of intelligent development based on data and computing, bringing new drugs and disease treatment programs to mankind.
In fact, there are artificial intelligence figures in the top ten scientific breakthroughs published by Science magazine in recent two years.
On December 17th this year, Science published the list of the top ten scientific breakthroughs in 221, and AlphaFold 2 and RoseTTA-fold, two technologies based on artificial intelligence technology, topped the list. This time, AI technology accurately predicted almost all protein structures expressed by human beings.
On December 17th, 22, Science published its top ten scientific breakthroughs in 22, among which AlphaFold artificial intelligence accurately predicted the three-dimensional structure of protein for the first time, and its accuracy was comparable to that of cryoelectron microscopy, X-ray crystallography and other experimental technologies. The researchers pointed out that since the precise shape of protein determines its biochemical function, this new development can help researchers discover the pathogenesis of diseases and develop new drugs.
The Zhongguancun AI new drug research and development platform, which is completed this time, includes high-performance computing center, Qualcomm automation equipment, drug verification laboratory and other functional modules, and can realize the whole process of drug discovery from data generation to algorithm training to wet experiment verification.
"In 219, the output value of artificial intelligence in Beijing reached 17 billion yuan, and the number of artificial intelligence-related enterprises exceeded 1,5." Wang Wenli, general manager of Zhongguancun Life Science Park, introduced at the ceremony that Zhongguancun AI new drug research and development platform, with its unique location advantage, can fully integrate artificial intelligence technology, biomedical research and development resources and clinical data resources, and widely empower domestic and foreign biotechnology enterprises through AI technology, greatly shortening the cycle of new drug research and development, reducing research and development costs, rapidly promoting the growth of new drug research and development enterprises, and promoting the high-quality development of national pharmaceutical health industry.